Veterinary Medicines

CLINDASEPTIN 25 MG/ML ORAL SOLUTION FOR CATS AND DOGS

Authorised
  • Clindamycin hydrochloride
Download as PDF

Product identification

Medicine name:
CLINDASEPTIN 25 MG/ML ORAL SOLUTION FOR CATS AND DOGS
Clindaseptin 25 mg/ml Oral lösning
Active substance:
  • Clindamycin hydrochloride
Target species:
  • Dog
  • Cat
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Clindamycin hydrochloride
    27.15
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Oral solution
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01FF01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Sweden
Package description:
  • Carton box containing clear polyethylene terephthalate (PET) bottle of 22 ml with a low density polyethylene measuring syringe
  • Carton box containing clear polyethylene terephthalate (PET) bottle of 22 ml with a low density polyethylene measuring syringe

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Chanelle Pharmaceuticals Manufacturing Limited
Marketing authorisation date:
Manufacturing sites for batch release:
  • Chanelle Pharmaceuticals Manufacturing Limited
Responsible authority:
  • Swedish Medical Products Agency
Authorisation number:
  • 46081
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0236/001
Concerned member states:
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • Germany
  • Ireland
  • Italy
  • Netherlands
  • Portugal
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Swedish (PDF)
Published on: 26/04/2022
Download

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Swedish (PDF)
Published on: 26/04/2022
Download